Application of fructus amomi water extract and / or vanillic acid in preparation of medicine for preventing and / or treating preeclampsia

Through the application of Amomum villosum water extract and vanillic acid, the gastrointestinal adverse reactions and operation difficulties in preeclampsia treatment were solved, and the preeclampsia hypertension, proteinuria, placental dysfunction and intestinal barrier damage were achieved. Effective treatment provides a simple and safe treatment plan.

CN118924855APending Publication Date: 2024-11-12SOUTHERN MEDICAL UNIVERSITY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411007034.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing preeclampsia treatment drugs have gastrointestinal adverse reactions and are difficult to operate, especially in low- and middle-income countries that are simple, safe and effective treatment options.

Method used

Prepared by grinding, soaking, decocting and freeze-dried using Amomum villosum water extract and/or vanillic acid, for the prevention and treatment of preeclampsia-related symptoms such as hypertension, proteinuria, placental dysfunction and intestinal barrier damage , treated by oral or subcutaneous injection.

Benefits of technology

Significantly reduce the expression of intestinal inflammatory factors, increase the intestinal tight junction protein, repair the intestinal barrier, enrich the intestinal beneficial bacteria, and effectively alleviate the hypertension, proteinuria, placental weight reduction and fetal intrauterine growth caused by preeclampsia Restricted, providing a more comprehensive and safe treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924855A_ABST
    Figure CN118924855A_ABST
Patent Text Reader

Abstract

The invention discloses application of a fructus amomi water extract and / or vanillic acid in preparation of a medicine for preventing and / or treating preeclampsia. The invention also discloses application of the fructus amomi water extract and / or vanillic acid in preparation of a medicine for preventing and / or treating hypertension caused by preeclampsia, or a medicine for preventing and / or treating proteinuria caused by preeclampsia, or a medicine for reversing weight reduction of placenta caused by preeclampsia, or a medicine for recovering intrauterine growth limitation of fetuses caused by preeclampsia, or a medicine for preventing and / or treating hypertension caused by preeclampsia, or a medicine for preventing and / or treating proteinuria caused by preeclampsia. Or a medicine for recovering placenta tissue pathological injury or placenta dysfunction caused by preeclampsia, or a medicine for reversing placenta efficiency reduction caused by preeclampsia, or a medicine for repairing colon barrier injury or intestinal permeability increase caused by preeclampsia; or the bifidobacterium bifidum in the intestinal tract of a preeclampsia patient is enriched. The traditional Chinese medicine composition overcomes the limitations of single effect and adverse reaction of gastrointestinal tracts in the current preeclampsia treatment medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and particularly relates to application of an Amomum villosum water extract and / or vanillic acid in preparing a medicine for preventing and / or treating preeclampsia. Background Art

[0002] Pre-eclampsia (PE) is a complex pregnancy-specific disease with new-onset hypertension (systolic blood pressure ≥140 mmHg and / or diastolic blood pressure ≥90 mmHg) and proteinuria as the main clinical features at 20 weeks of pregnancy, often accompanied by neurological symptoms such as headache, convulsions, and visual impairment. In severe cases, it can lead to damage to organs such as the liver and kidneys, leading to systemic multiple organ failure and even maternal and infant death. Compared with normal pregnant women, patients with preeclampsia have a shorter life expectancy in the future, and their risks of stroke, cardiovascular disease, and diabetes are significantly increased. In addition, infants with preeclampsia also have a significantly increased risk of premature birth, neurodevelopmental disorders, and cardiovascular and metabolic diseases. Therefore, the prevention and treatment of preeclampsia is of great significance to promoting reproductive health.

[0003] The pathogenesis of PE is complex and involves a variety of pathological factors, including abnormal uterine-placental vascular structure, endothelial dysfunction, inflammatory immune overactivation, and genetic factors. At present, the "two-stage model" theory is clinically recognized as the main pathogenesis of PE. Under normal pregnancy conditions, the uterine spiral arteries of pregnant women will expand to 5-10 times the normal size, developing into wider, broader, and higher-flow arteries, which deliver a large amount of blood, oxygen, and nutrients to the fetus to ensure the normal development of the fetus in the uterus. When preeclampsia occurs, the mother's uterine spiral arteries are narrowed due to abnormal remodeling, which can lead to insufficient blood and oxygen supply to the placenta, and then cause placental dysfunction, which is not conducive to the delivery of blood oxygen and nutrients, resulting in restricted fetal growth and development. In order to compensate for the insufficient blood oxygen supply to the placenta, the mother increases blood pressure by constricting blood vessels, driving more blood to the placenta, leading to the occurrence of hypertension, which is one of the main clinical symptoms of PE. In addition, due to maternal placental dysfunction, a large number of placental-derived bioactive substances are released into the maternal blood circulation, including anti-angiogenic factors, inflammatory cytokines, etc., which can induce endothelial dysfunction and inflammatory response, further impair the normal contraction and relaxation of blood vessels, reduce blood flow to various organs, and lead to multiple organ dysfunction such as liver, kidney, and lung, especially involving renal tissue, damaging glomerular filtration function, thereby causing urinary protein production, which is also one of the main clinical symptoms of PE. In addition, recent studies have shown that intestinal flora imbalance can lead to immune imbalance and impaired intestinal barrier function, promote the migration of pathogenic bacteria (such as Fusobacterium nucleatum) into the uterine cavity, and ultimately cause placental inflammation, leading to placental dysplasia, thereby aggravating the pathological progression of PE.

[0004] At present, the treatment strategies for preeclampsia mainly include preventive treatment and symptomatic treatment. According to the "Recommendations for Clinical Trials on Screening and Prevention of Preeclampsia in Single Pregnancy" issued by the International Federation of Gynecology and Obstetrics (FIGO), pregnant women with high risk of preeclampsia can take low-dose (<300 mg / day) aspirin orally every day from 12-16 weeks of pregnancy to reduce the occurrence of preeclampsia. In addition, the "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders Complicating Pregnancy (2020)" recommends taking oral labetalol, nifedipine and other drugs to control high blood pressure, and intravenous magnesium sulfate to reduce the occurrence of convulsions and spasms. However, there are still many adverse reactions to existing treatments. Preventive drug aspirin can cause gastrointestinal symptoms such as nausea, vomiting, and upper abdominal pain. The antihypertensive drug labetalol, as a negative cardiac inotropic drug, can promote pulmonary edema and heart failure and may cause bronchospasm. In addition, symptoms of headache and nausea may occur within 24 hours after taking the drug. As a calcium channel antagonist, nifedipine can rapidly dilate blood vessels and thus lower blood pressure, but it is accompanied by adverse reactions such as severe headache (especially within 24 hours of taking the medicine), dizziness, flushing, palpitations, and ankle swelling. Sublingual administration of nifedipine is supported for the rapid correction of severe hypertension in pregnant women, but it may lead to reduced placental perfusion, causing acute fetal distress. In addition, the use of magnesium sulfate in patients with preeclampsia can reduce the risk of eclamptic attacks by 58%. Because intramuscular injection can cause bruising or abscesses, the best way to administer magnesium sulfate is intravenous administration. However, because intravenous administration is difficult to operate and requires professional medical skills, and eclampsia is more common in low- and middle-income countries than in high-income countries, it is very important to find a safe and effective drug for the treatment of preeclampsia that is easy to administer. Summary of the invention

[0005] In order to solve the deficiencies in the prior art, the present invention aims to provide an application of an Amomum villosum water extract and / or vanillic acid in the preparation of a drug for preventing and / or treating preeclampsia.

[0006] Amomum villosum Lour. is the dried mature fruit of the herbaceous plant of the ginger family. It is one of the four major southern medicines in my country and has the effects of removing dampness and stimulating appetite, warming the spleen and stopping diarrhea, regulating qi and stabilizing pregnancy. Amomum villosum is composed of a variety of chemical substances, including volatile components (borneol acetate, borneol, etc.) and non-volatile components (polysaccharides, flavonoids, etc.). The present invention finds that the water extract of Amomum villosum and its main component vanillic acid play an important role in preventing and treating preeclampsia.

[0007] The specific technical solutions of the present invention are as follows:

[0008] The present invention provides application of Amomum villosum water extract and / or vanillic acid in preparing medicine for preventing and / or treating preeclampsia.

[0009] The present invention also provides the use of the Amomum villosum water extract and / or vanillic acid in preparing a medicine for preventing and / or treating hypertension caused by preeclampsia.

[0010] The present invention also provides the use of the Amomum villosum water extract and / or vanillic acid in preparing a medicine for preventing and / or treating proteinuria caused by preeclampsia.

[0011] The present invention also provides the use of the Amomum villosum water extract and / or vanillic acid in preparing a medicine for reversing the reduction of placental weight caused by preeclampsia.

[0012] The present invention also provides the use of the Amomum villosum water extract and / or vanillic acid in preparing a medicine for restoring fetal intrauterine growth restriction caused by preeclampsia.

[0013] The present invention also provides the use of the Amomum villosum water extract and / or vanillic acid in preparing a medicine for restoring pathological damage of placental tissue or abnormal placental function caused by preeclampsia.

[0014] The present invention also provides the use of the Amomum villosum water extract and / or vanillic acid in preparing a medicine for reversing the reduced placental efficiency caused by preeclampsia.

[0015] The present invention also provides the use of Amomum villosum water extract and / or vanillic acid in preparing a drug for repairing colon barrier damage or increased intestinal permeability caused by preeclampsia, or a drug for enriching Bifidobacterium bifidum in the intestine of patients with preeclampsia.

[0016] Furthermore, the Amomum villosum water extract is prepared by the following method:

[0017] 1) grinding and crushing the Amomum villosum, and soaking it in distilled water to obtain soaked Amomum villosum;

[0018] 2) taking distilled water, boiling it over high heat, adding the soaked Amomum villosum, decocting it over low heat, filtering, and obtaining filtrate A and medicinal residue;

[0019] 3) Take distilled water, boil it over high heat, add the medicinal residue, simmer over low heat, filter, and obtain filtrate B and medicinal residue;

[0020] 4) Repeat step 3) to obtain filtrate C;

[0021] 5) The filtrates are combined, concentrated and freeze-dried to obtain freeze-dried powder of Amomum villosum, i.e., the water extract of Amomum villosum.

[0022] Furthermore, the distilled water soaking time in step 1) is 1-6 hours;

[0023] And / or, the weight ratio of distilled water to Amomum villosum in step 2) and step 3) is 10:1-50:1;

[0024] And / or, the time of slow-cooking in step 2) and step 3) is 5-30 min.

[0025] The beneficial effects of the present invention are:

[0026] The present invention simulates the pathological state of preeclampsia by subcutaneous injection of nitroso-L-arginine methyl ester solution (125 mg / kg), and intragastric administration of Amomum villosum water extract (520 mg / kg) or vanillic acid (70 mg / kg) is performed once a day from the 9th day of pregnancy until the end of pregnancy. It is found that oral administration of Amomum villosum water extract or its main component vanillic acid has a good therapeutic effect on preeclampsia.

[0027] Compared with preventive drugs such as aspirin and antihypertensive drugs such as labetalol, which have gastrointestinal adverse reactions, oral administration of Amomum villosum water extract can significantly reduce the expression of colon inflammatory factors, increase the content of tight junction proteins, thereby repairing the intestinal barrier and reducing intestinal permeability. At the same time, oral administration of Amomum villosum water extract and vanillic acid can significantly enrich the beneficial intestinal bacteria Bifidobacterium bifidum, reshape the intestinal microecology, and show a more comprehensive therapeutic effect, providing a new therapeutic drug for the prevention or treatment of preeclampsia.

[0028] Compared with drugs with single therapeutic effects such as antihypertensive drug labetalol and antispasmodic drug magnesium sulfate, oral administration of Amomum villosum water extract and vanillic acid can effectively relieve hypertension, proteinuria, reduced placental weight, changes in placental function, intrauterine growth restriction and reduced placental efficiency caused by preeclampsia. In view of the limitation of gastrointestinal adverse reactions of existing drugs, oral administration of Amomum villosum water extract can significantly reduce colon inflammation caused by preeclampsia, increase the content of tight junction proteins, thereby repairing the intestinal barrier and reducing intestinal permeability. At the same time, oral administration of Amomum villosum water extract and vanillic acid can significantly enrich the beneficial intestinal bacteria Bifidobacterium bifidum, showing a more comprehensive and safe therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 Comparison of blood pressure of mice in each group in Example 1 (n=6). Wherein, a represents the comparison of systolic blood pressure between NP group and PE group on the corresponding date; b represents the comparison of systolic blood pressure between NP group and WOA group on the corresponding date; c represents the comparison of systolic blood pressure between NP group and VA group on the corresponding date; d represents the comparison of systolic blood pressure between PE group and WOA group on the corresponding date; e represents the comparison of systolic blood pressure between PE group and VA group on the corresponding date; f represents the comparison of systolic blood pressure between WOA group and VA group on the corresponding date.

[0030] Figure 2 Comparison of urine protein content in each group of mice in Example 2 (n=6).

[0031] Figure 3 Comparison of placenta weights of mice in each group in Example 3 (n=6).

[0032] Figure 4 Comparison of the area ratios of the placental labyrinth region to the connecting region in each group of mice in Example 4 (n=6); the scale bar in the figure is 1000 μm.

[0033] Figure 5 Comparison of fetal weights of mice in each group in Example 5 (n=6).

[0034] Figure 6 Comparison of the placenta efficiency of each group of mice in Example 6 (n=6).

[0035] Figure 7 The relative mRNA expression levels of inflammatory factors in the colon, the staining and quantification results of tight junction protein immunohistochemistry, and the comparison of endotoxin content in serum of each group of mice in Example 7 (n=6).

[0036] Figure 8 Comparison of the relative mRNA expression levels of Bifidobacterium bifidum in the feces of each group of mice in Example 8 (n=6). DETAILED DESCRIPTION

[0037] In order to understand the present invention more clearly, the present invention is further described with reference to the following examples and accompanying drawings. The examples are only used for explanation and are not intended to limit the present invention in any way. In the examples, each raw material reagent is commercially available, and the experimental methods without specifying specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.

[0038] 1. Drug ingredients

[0039] (1) The water extract of Amomum villosum Lour. (WOA) in the embodiment of the present invention is prepared by the following preparation method:

[0040] 1) Accurately weigh 50.0 g of Amomum villosum, crush it and soak it in appropriate amount of distilled water for 1 hour before use;

[0041] 2) Take 500 mL of distilled water (10 times the weight of Amomum villosum), boil it over high heat, add the soaked Amomum villosum, simmer for 5 min over low heat, and filter to obtain filtrate A;

[0042] 3) Add the residue back into boiling distilled water 10 times the weight of Amomum villosum, simmer for 5 min, filter, and obtain filtrate B;

[0043] 4) Repeat step 3) to obtain filtrate C;

[0044] 5) The three filtrates were combined, concentrated and freeze-dried to obtain freeze-dried powder of Amomum villosum, which was dried and sealed and stored at room temperature.

[0045] (2) Vanillic acid (VA), with the chemical formula C8H8O4 and molecular weight 168.147, is the component with the highest content in the water extract of Amomum villosum.

[0046] 2. Experimental Animals

[0047] Male and female C57BL / 6 mice (8–10 weeks, weighing 18–20 g) were purchased from SPF (Beijing, China) Biotechnology Co., Ltd. (Beijing, China). Mice were housed under standard light and dark cycles (12 h:12 h) with free access to food and water. After one week of acclimation, healthy male mice were mated with female mice at a ratio of 1:2 overnight. Female mice with sperm plugs were considered pregnant, and this day was defined as gestational day (GD0). All animal studies were performed in accordance with the protocols and guidelines approved by the Animal Ethics Committee of the Laboratory Animal Center of Southern Medical University.

[0048] 3. Experimental reagents

[0049]

[0050] Mouse serum soluble fms-like tyrosine kinase-1 (sFlt-1) ELISA Kit Jiangsu ELISA Industry Co., Ltd.

[0051] Mouse Placental Growth Factor (PLGF) ELISA Kit Jiangsu ELISA Industrial Co., Ltd.

[0052] Mouse angiogenic factor (VEGF) ELISA kit Jiangsu ELISA Industrial Co., Ltd.

[0053] Animal Tissue Total RNA Extraction Kit Chengdu Fuji Biotechnology Co., Ltd.

[0054] HiScript IIQ RT SuperMix for qPCR Nanjing Novozymes Biotech Co., Ltd. Limited Company

[0055] GoTaq qPCR Master Mix Nanjing Novozymes Biotech Co., Ltd. Limited Company

[0056] 96-well fluorescent quantitative PCR plate Mona Biotechnology Co., Ltd.

[0057] 4. Drug preparation

[0058] 1) N-nitro-L-arginine methyl ester (L-NAME) solution: Weigh 125 mg of L-NAME powder, dilute to 10 mL with saline, and store at -20°C in the dark.

[0059] 2) Amomum villosum water extract solution: accurately weigh 260 mg of freeze-dried powder of Amomum villosum water extract, dilute to 5 mL with phosphate buffered saline, mix thoroughly, and use immediately after preparation.

[0060] 3) Vanillic acid solution: Accurately weigh 35 mg of vanillic acid powder, dilute to 5 mL with phosphate buffered saline, mix thoroughly, and use immediately after preparation.

[0061] 5. Establishment and evaluation of preeclampsia model

[0062] 1) Establishment of preeclampsia model.

[0063] Starting from GD9, pregnant mice were subcutaneously injected with 125 mg / kg of nitroso-L-arginine methyl ester (L-NAME) solution every day for 9 days.

[0064] 2) Evaluation of preeclampsia model

[0065] Blood pressure: The model was successfully established when the systolic blood pressure of the mice in the model group was >110 mmHg.

[0066] Proteinuria: The model was successfully established when the urine protein content of mice in the model group was significantly higher than 15.0 mg / dL.

[0067] 6. Real-time fluorescence quantitative PCR

[0068] 1) RNA reverse transcription reaction

[0069] According to the method described in the reverse transcription kit, prepare a 20 μL total reaction system. Add the RNA required for the sample and 4 μL of HiScript IIQ RT SuperMix for qPCR reagent to a 200 μL PCR tube, and add ddH2O to 20 μL. Place the PCR tube in a PCR amplification instrument and perform the following operating conditions: 50°C, 15 min; 85°C, 5 s; 4°C, ∞. After the reaction is completed, centrifuge, mark the time, and store the obtained cDNA at -80°C for later use.

[0070] 2) Real-time quantitative PCR (RT-qPCR)

[0071] All reverse transcription products were subjected to real-time fluorescence quantitative PCR, and the reaction system is shown in Table 1. The primer sequences of related genes are shown in Table 2, and a two-step PCR amplification system was used, and the method settings are shown in Table 3.

[0072] Table 1 PCR reaction system

[0073]

[0074] Table 2 Primer sequences

[0075]

[0076] Table 3 RT-qPCR reaction procedure

[0077]

[0078] Data processing: Gapdh was used as the internal reference gene, and the relative expression level of the target gene was calculated by the 2-ΔΔCt method.

[0079] Example 1: Amomum villosum water extract and vanillic acid can significantly restore hypertension caused by preeclampsia

[0080] Hypertension is the most critical clinical indicator of preeclampsia. This example investigates the effects of Amomum villosum water extract and vanillic acid on the blood pressure of mice with preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum water extract group (WOA, n = 6), and a vanillic acid group (VA, n = 6). Mice in the WOA group and the VA group were gavaged with Amomum villosum water extract (520 mg / kg) and vanillic acid (70 mg / kg) respectively from the 9th day of pregnancy (GD 9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with an equal volume of 0.9% saline. Once a day for 9 days.

[0081] The results are as follows Figure 1 ,The results showed that the blood pressure of mice in the preeclampsia model group was significantly higher than that in the normal pregnancy group, the Amomum villosum water extract group and the vanillic acid group after GD9, indicating that both WOA and VA can significantly reduce the blood pressure of mice in preeclampsia.

[0082] Example 2: Amomum villosum water extract and vanillic acid can significantly restore proteinuria caused by preeclampsia

[0083] Proteinuria is one of the key clinical indicators of preeclampsia. In this example, subcutaneous injection of nitroso-L-arginine methyl ester (L-NAME) solution was used to simulate the disease state during the natural onset of preeclampsia, and the effects of Amomum villosum water extract and vanillic acid on urinary protein in mice with preeclampsia were investigated. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum water extract group (WOA, n = 6), and a vanillic acid group (VA, n = 6). Mice in the WOA group and the VA group were gavaged with Amomum villosum water extract (520 mg / kg) and vanillic acid (70 mg / kg) respectively from the 9th day of pregnancy (GD9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0084] Results Figure 2 The results showed that the urine protein content of preeclampsia model mice was significantly higher than that of the normal pregnancy group, and the urine protein level of model mice was significantly downregulated after intervention with Amomum villosum water extract or vanillic acid, indicating that both WOA and VA can significantly reduce the proteinuria symptoms of preeclampsia model mice.

[0085] Example 3: Amomum villosum water extract and vanillic acid can increase the placental weight of preeclampsia mice

[0086] The placenta is rich in blood vessels and nutrients, which provide the necessary substances for fetal growth and development. This example investigates the effect of Amomum villosum water extract and vanillic acid on the weight of the placenta in mice with preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum water extract group (WOA, n = 6), and a vanillic acid group (VA, n = 6). The mice in the WOA group and the VA group were gavaged with Amomum villosum water extract (520 mg / kg) and vanillic acid (70 mg / kg) respectively from the 9th day of pregnancy (GD9), and the mice in the normal pregnancy group and the preeclampsia model group were gavaged with the same volume of 0.9% normal saline. Once a day for 9 days.

[0087] The results are as follows Figure 3 The results showed that compared with the mice in the normal pregnancy group, the placental weight of the mice in the preeclampsia group was significantly reduced, while the intervention with Amomum villosum water extract or vanillic acid significantly reversed the decrease in placental weight, indicating that the intervention of WOA and VA is beneficial to the growth and development of the placenta in preeclampsia.

[0088] Example 4: Amomum villosum water extract and vanillic acid can restore placental dysfunction

[0089] The placenta is mainly divided into three parts: the decidual region, the connecting region and the labyrinth region. The placental labyrinth region is mainly involved in the synthesis of hormones and cytokines (such as angiogenic factors and anti-angiogenic factors), maintaining normal placental function and fetal growth. The placental connecting region is mainly responsible for the exchange of oxygen, nutrients and metabolic waste. This example investigates the effect of Amomum villosum water extract and vanillic acid on placental function in mice with preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum water extract group (WOA, n = 6), and a vanillic acid group (VA, n = 6). The mice in the WOA group and the VA group were gavaged with Amomum villosum water extract (520 mg / kg) and vanillic acid (70 mg / kg) respectively from the 9th day of pregnancy (GD9), and the mice in the normal pregnancy group and the preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0090] HE staining results Figure 4 As shown in the figure. The area ratio of the labyrinth area to the connection area of ​​the placenta of PE mice was significantly higher than that of NP mice, indicating that the placental structure of PE mice was pathologically damaged. This phenomenon was reversed after intervention with WOA or VA, indicating that WOA and VA can repair the pathological damage of the placental tissue of PE mice and restore the abnormal placental function.

[0091] Example 5: Amomum villosum water extract and vanillic acid can restore intrauterine growth restriction in pregnant mice with preeclampsia

[0092] Fetal growth restriction is one of the main complications of preeclampsia. This example investigates the effects of Amomum villosum water extract and vanillic acid on fetal growth in mice with preeclampsia. In this example, mice were randomly divided into 4 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), an Amomum villosum water extract group (WOA, n = 6), and a vanillic acid group (VA, n = 6). Mice in the WOA group and the VA group were gavaged with Amomum villosum water extract (520 mg / kg) and vanillic acid (70 mg / kg) respectively from the 9th day of pregnancy (GD9), and mice in the normal pregnancy group and the preeclampsia model group were gavaged with an equal volume of 0.9% saline. Once a day for 9 days.

[0093] The results are as follows Figure 5 The results showed that compared with the mice in the normal pregnancy group, the fetal weight of the mice in the preeclampsia group was significantly reduced, while the intervention of WOA or VA could significantly reverse the decrease in fetal weight, indicating that WOA and VA can promote fetal growth and development in PE pregnant mice.

[0094] Example 6: Amomum villosum water extract and vanillic acid can significantly restore placental efficiency

[0095] Placental efficiency refers to the ratio of fetal weight to total placental weight. In preeclampsia, placental efficiency is reduced due to abnormal placental growth and development and fetal intrauterine growth restriction. This example investigates the effect of Amomum villosum water extract and vanillic acid on placental efficiency in preeclampsia. In this example, mice were randomly divided into 4 groups: normal pregnancy group (NP, n = 6), preeclampsia model group (PE, n = 6), Amomum villosum water extract group (WOA, n = 6), and vanillic acid group (VA, n = 6). Mice in the WOA group and VA group were gavaged with Amomum villosum water extract (520 mg / kg) and vanillic acid (70 mg / kg) respectively from the 9th day of pregnancy (GD9), and mice in the normal pregnancy group and preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0096] like Figure 6 As shown in the data, compared with the model group, the placental efficiency of PE pregnant mice was significantly increased after WOA or VA intervention, indicating that both WOA and VA can restore the PE-induced decrease in placental efficiency.

[0097] Example 7: Amomum villosum water extract can repair colon barrier damage caused by preeclampsia

[0098] In recent years, the imbalance of intestinal microecology has been considered as one of the pathogenesis of PE. Due to intestinal flora disorder, aggravated intestinal inflammation, and damaged intestinal barrier, pathogenic bacteria are transferred from the intestine to the placenta through the blood circulation, resulting in abnormal immune response, thereby inducing PE. This example investigates the effects of Amomum villosum water extract and vanillic acid on colon barrier damage in preeclampsia. In this example, mice were randomly divided into 3 groups: a normal pregnancy group (NP, n = 6), a preeclampsia model group (PE, n = 6), and an Amomum villosum water extract group (WOA, n = 6). The mice in the WOA group were gavaged with Amomum villosum water extract (520 mg / kg) from the 9th day of pregnancy (GD9), and the mice in the normal pregnancy group and the preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0099] The results are as follows Figure 7 As shown in AC, compared with the model group, WOA intervention significantly reduced the expression of inflammatory factors (Il-6, Il-1β, Tnf-α) in the colon of preeclampsia mice, and significantly increased the levels of tight junction proteins (ZO-1, Occludin and Claudin-1). In addition, the intestine contains a large number of Gram-negative bacteria, and endotoxin (LPS) is a heat-resistant lipopolysaccharide molecule on the cell wall of Gram-negative pathogens. When the intestinal barrier function is impaired, LPS will enter the blood and transfer to the surrounding tissues and organs, causing damage to the surrounding tissues and organs. The results are shown in Figure 7 As shown in D, compared with the model group, the LPS in the serum of PE pregnant mice was significantly reduced after WOA intervention. In conclusion, WOA repaired the PE-induced colon barrier damage.

[0100] Example 8: Amomum villosum water extract and vanillic acid can significantly enrich Bifidobacterium bifidum

[0101] Bifidobacterium bifidum (B.bifidum) is an important intestinal beneficial bacteria. Supplementation of B.bifidum during maternal pregnancy can promote placental growth, nutrient transport and fetal growth and development, and participate in shaping the construction of intestinal microbiota and the development of the immune system of offspring. This example investigates the effects of Amomum villosum water extract and vanillic acid on Bifidobacterium bifidum in the feces of mice with preeclampsia. In this example, mice were randomly divided into 3 groups: a preeclampsia model group (PE, n=6), an Amomum villosum water extract group (WOA, n=6), and a vanillic acid group (VA, n=6). Mice in the WOA group and the VA group were gavaged with Amomum villosum water extract (520 mg / kg) and vanillic acid (70 mg / kg) respectively from the 9th day of pregnancy (GD9), and mice in the preeclampsia model group were gavaged with the same volume of 0.9% saline. Once a day for 9 days.

[0102] The results are as follows Figure 8 As shown, compared with the model group, the mRNA level of B. bifidum in the feces of PE pregnant mice was significantly increased after WOA or VA intervention, indicating that both WOA and VA were significantly enriched in Bifidobacterium bifidum.

[0103] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of Amomum villosum water extract and / or vanillic acid in the preparation of a drug for preventing and / or treating preeclampsia.

2. Use of Amomum villosum water extract and / or vanillic acid in the preparation of a drug for preventing and / or treating hypertension caused by preeclampsia.

3. Use of Amomum villosum water extract and / or vanillic acid in the preparation of a drug for preventing and / or treating proteinuria caused by preeclampsia.

4. Use of Amomum villosum water extract and / or vanillic acid in the preparation of a drug for reversing placental weight reduction caused by preeclampsia.

5. Use of Amomum villosum water extract and / or vanillic acid in the preparation of a drug for restoring fetal intrauterine growth restriction caused by preeclampsia.

6. Use of Amomum villosum water extract and / or vanillic acid in the preparation of a drug for restoring pathological damage to placental tissue or abnormal placental function caused by preeclampsia.

7. Use of Amomum villosum water extract and / or vanillic acid in the preparation of a drug for reversing reduced placental efficiency caused by preeclampsia.

8. Use of Amomum villosum water extract and / or vanillic acid in the preparation of a drug for repairing colon barrier damage or increased intestinal permeability caused by preeclampsia, or a drug for enriching Bifidobacterium bifidum in the intestine of patients with preeclampsia.

9. The use according to any one of claims 1 to 8, characterized in that: The Amomum villosum water extract is prepared by the following method: 1) grinding and crushing the Amomum villosum, and soaking it in distilled water to obtain soaked Amomum villosum; 2) taking distilled water, boiling it over high heat, adding the soaked Amomum villosum, decocting it over low heat, filtering, and obtaining filtrate A and medicinal residues; 3) Take distilled water, boil it over high heat, add the medicinal residue, simmer over low heat, filter, and obtain filtrate B and medicinal residue; 4) Repeat step 3) to obtain filtrate C; 5) The filtrates are combined, concentrated and freeze-dried to obtain freeze-dried powder of Amomum villosum, i.e., the water extract of Amomum villosum.

10. The use according to claim 9, characterized in that: The distilled water soaking time in step 1) is 1-6 hours; And / or, the weight ratio of distilled water to Amomum villosum in step 2) and step 3) is 10:1-50:1; And / or, the time of slow-cooking in step 2) and step 3) is 5-30 min.

Citation Information

Cited By

  • Use of water extract of amomi fructus and / or vanillic acid in preparation of drug for preventing and / or treating preeclampsia

    WO2026021445A1